NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

Migration, Crosslink

📖

NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-nqo1

📖 Wiki Page

protein1982 wordssynced 2026-04-02

title: NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

NQO1 (NAD(P)H Quinone Dehydrogenase 1) Protein

| Property | Value |
|----------|-------|
| Protein Name | NAD(P)H quinone dehydrogenase 1 |
| Gene | NQO1 |
| UniProt ID | P15559 |
| PDB ID | 1QBG, 1R1M, 5EHA, 6BQD |
| Molecular Weight | ~31 kDa |
| Subcellular Localization | Cytoplasm, also nucleus (minor) |
| Protein Family | NAD(P)H dehydrogenase (quinone) family |
| Expression | Ubiquitous, high in brain, liver, kidney |

</div>

Overview

NAD(P)H quinone dehydrogenase 1 (NQO1), also known as DT-diaphorase, is a 274-amino acid flavoprotein that serves as a critical detoxification enzyme in cellular redox homeostasis. Uniquely among enzymes, NQO1 catalyzes two-electron reduction of quinones, bypassing the one-electron reduction that generates toxic semiquinone radicals[@bianchet2004]. This function is particularly important in the brain, where oxidative stress and quinone metabolism play central roles in neurodegeneration.

...

title: NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

NQO1 (NAD(P)H Quinone Dehydrogenase 1) Protein

| Property | Value |
|----------|-------|
| Protein Name | NAD(P)H quinone dehydrogenase 1 |
| Gene | NQO1 |
| UniProt ID | P15559 |
| PDB ID | 1QBG, 1R1M, 5EHA, 6BQD |
| Molecular Weight | ~31 kDa |
| Subcellular Localization | Cytoplasm, also nucleus (minor) |
| Protein Family | NAD(P)H dehydrogenase (quinone) family |
| Expression | Ubiquitous, high in brain, liver, kidney |

</div>

Overview

NAD(P)H quinone dehydrogenase 1 (NQO1), also known as DT-diaphorase, is a 274-amino acid flavoprotein that serves as a critical detoxification enzyme in cellular redox homeostasis. Uniquely among enzymes, NQO1 catalyzes two-electron reduction of quinones, bypassing the one-electron reduction that generates toxic semiquinone radicals[@bianchet2004]. This function is particularly important in the brain, where oxidative stress and quinone metabolism play central roles in neurodegeneration.

NQO1 is one of the most induced enzymes in response to oxidative stress, regulated primarily through the Nrf2-ARE (antioxidant response element) pathway. Its activity is essential for maintaining cellular redox balance, regenerating antioxidant compounds, and protecting against genotoxic stress. The common missense variant C609T (P187S), present in approximately 20% of the population, reduces NQO1 activity by approximately 70% and has been associated with increased risk for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@dinkova2015].

Structure

The NQO1 protein exhibits unique structural features that enable its distinctive catalytic function[@bianchet2004]:

Domain Architecture

Rossmann Fold (aa 1-150): The N-terminal domain binds the NAD(P)H cofactor. Unlike most dehydrogenases, NQO1 shows equal affinity for NADH and NADPH, reflecting its role as a universal two-electron reductant.
FAD Binding Site (aa 150-200): Contains a tightly bound FAD cofactor (1:1 stoichiometry). The FAD is covalently linked to a cysteine residue (Cys105) and is essential for catalysis. The isoalloxazine ring of FAD undergoes redox cycling during catalysis.
Active Site (aa 180-230): The site of two-electron reduction. Contains key residues for substrate binding and catalysis, including Tyr128, Asp150, and His161.
Proline-Rich Region (aa 80-100): A unique feature of NQO1 among the quinone oxidoreductase family, with multiple proline residues of unknown function.
Dimeric Interface: NQO1 functions as a homodimer. Each monomer has a molecular weight of ~31 kDa, and the dimer has a total mass of ~62 kDa. Dimerization is required for stability and activity.

Catalytic Mechanism

Mermaid diagram (expand to render)

The catalytic mechanism is unique:

NQO1 reduces FAD using NAD(P)H, forming FADH2

The reduced flavin transfers two electrons to the quinone substrate

This bypasses semiquinone radical formation

The resulting hydroquinone is stable and can be conjugated for excretion

Genetic Variants

| Variant | Frequency | Effect |
|---------|-----------|--------|
| C609T (P187S) | ~20% Caucasian | 70% reduced activity |
| R139W | Rare | Loss of function |
| P34S | Rare | Variable effect |

Normal Function in the Nervous System

NQO1 performs essential detoxification and antioxidant functions in neurons and glia:

Quinone Detoxification

One-electron vs. two-electron reduction: Most enzymes reduce quinones via one electron, generating semiquinone radicals that react with oxygen to form superoxide. NQO1 performs direct two-electron reduction, avoiding ROS generation.
Endogenous quinones: Metabolism of dopamine, norepinephrine, and other catecholamines generates quinones. NQO1 detoxifies these before they can form toxic oligomers or damage DNA.
Exogenous quinones: Environmental quinones from pesticides, industrial chemicals, and drugs are also substrates for NQO1.

Antioxidant Defense

Coenzyme Q10 (Ubiquinone) recycling: NQO1 reduces ubiquinone to ubiquinol, the active antioxidant form of coenzyme Q10. This is critical for mitochondrial electron transport chain protection.
Vitamin E metabolism: Tocopherol quinone (the oxidized form of vitamin E) is reduced by NQO1 back to active tocopherol.
Direct antioxidant effects: NQO1 can function as a direct antioxidant, quenching radicals through its flavin cofactor.

DNA and Protein Protection

DNA protection: Prevents oxidative DNA damage by reducing quinone genotoxins before they can form DNA adducts.
p53 stabilization: NQO1 stabilizes the tumor suppressor p53 by preventing its degradation, linking it to DNA damage responses.
Protein protection: Prevents protein cross-linking and aggregation caused by quinone-derived carbonyls.

Mitochondrial Function

ETC protection: By regenerating ubiquinol, NQO1 protects complex I and other components of the electron transport chain from oxidative damage.
Membrane protection: Lipid peroxidation generates quinones that NQO1 can reduce, preventing chain reaction lipid peroxidation.

Cellular Signaling

Nrf2 regulation: NQO1 is both a target and regulator of Nrf2, creating a positive feedback loop in antioxidant response.
p53 pathway: NQO1-p53 interaction affects cell cycle and apoptosis decisions.

Role in Disease

Alzheimer's Disease (AD)

NQO1 deficiency contributes to AD pathogenesis through multiple interconnected mechanisms[@sanarico2019][@ross2018]:

Oxidative Stress

Reduced quinone detoxification leads to accumulation of toxic quinone species
Semiquinone formation from inefficient one-electron reduction increases ROS
NQO1 activity is reduced in AD brain, correlating with disease severity
The C609T variant is associated with increased AD risk

Amyloid Pathology

[Aβ](/proteins/amyloid-beta) (amyloid-beta) induces NQO1 deficiency:

Aβ exposure reduces NQO1 expression in neurons
Loss of NQO1 exacerbates Aβ-induced oxidative stress
NQO1 activity correlates inversely with amyloid burden
NQO1 can reduce Aβ-induced neurotoxicity in models

Mitochondrial Dysfunction

Coenzyme Q10 depletion affects the electron transport chain
Mitochondrial ROS increases, creating a vicious cycle
NQO1 deficiency in AD brain correlates with complex I impairment
Ubiquinol regeneration is critical for mitochondrial protection

Neuroinflammation

Quinone accumulation triggers microglial activation
NQO1 modulates inflammatory responses in astrocytes
NQO1 deficiency exacerbates neuroinflammation

Therapeutic Implications

Coenzyme Q10: NQO1 substrates for mitochondrial support (multiple trials)
Vitamin E: NQO1-mediated regeneration of tocopherol
Nrf2 activators: Increase NQO1 expression (sulforaphane, bardoxolone methyl)
Gene therapy: AAV-NQO1 in development

Parkinson's Disease (PD)

NQO1 has a particularly important role in PD due to dopamine metabolism:

Dopamine Quinones

Dopamine oxidation generates dopamine quinones (DQ)
NQO1 is the primary enzyme detoxifying DQ in dopaminergic neurons
NQO1 activity is high in substantia nigra under normal conditions
NQO1 deficiency allows DQ accumulation and neuronal death

Toxin Susceptibility

MPTP, 6-OHDA, and other parkinsonian toxins generate quinones
NQO1 protects against these toxins in model systems
NQO1 deficiency increases susceptibility to parkinsonian toxins

Alpha-Synuclein Interaction

[NQO1 modulates alpha-synuclein](/proteins/alpha-synuclein) (α-syn) aggregation:

Oxidative stress promotes α-syn oxidation and aggregation
NQO1 can reduce α-syn oxidation and oligomerization
NQO1 levels correlate inversely with α-syn pathology

Genetic Association

NQO1 polymorphisms modify PD risk
C609T variant associated with earlier onset and faster progression
Gene-environment interactions (e.g., pesticide exposure + variant)

Therapeutic Strategies

Nrf2 activators: Increase NQO1 expression
Coenzyme Q10: Support mitochondrial function
Quinone scavengers: Reduce quinone burden

Amyotrophic Lateral Sclerosis (ALS)

NQO1 activity is reduced in ALS motor cortex and spinal cord
Motor neurons have high oxidative stress and quinone production
NQO1 deficiency may contribute to motor neuron vulnerability
Therapeutic approaches mirror those in AD and PD

Huntington's Disease (HD)

Mutant huntingtin impairs NQO1 function
Quinone accumulation contributes to pathology
NQO1 restoration shows benefit in HD models

Mechanism of Action

Detoxification Pathways

Mermaid diagram (expand to render)

Nrf2-ARE Pathway

NQO1 is one of the premier Nrf2 target genes:

Oxidative stress activates Nrf2 (via Keap1 oxidation)

Nrf2 translocates to nucleus and binds ARE

NQO1 (and other antioxidants) are transcriptionally activated

Increased NQO1 provides feedback antioxidant protection

This pathway is impaired in neurodegenerative disease

Coenzyme Q10 Cycle

Mermaid diagram (expand to render)

Therapeutic Targeting

Clinical Status

| Approach | Status | Notes |
|----------|--------|-------|
| Coenzyme Q10 | Phase 2-3 | AD, PD, Huntington's trials |
| Nrf2 activators | Phase 2 | Sulforaphane, bardoxolone |
| Vitamin E | Completed | Mixed results |
| Gene therapy | Preclinical | AAV-NQO1 |

Experimental Approaches

Pharmacological Modulation

Nrf2 activators: Sulforaphane, oltipraz, bardoxolone methyl
Coenzyme Q10: Ubiquinol form better absorbed
Vitamin E: Tocopherol form
Direct NQO1 substrates: Increase activity

Gene Therapy

AAV-NQO1: Adeno-associated virus delivery
CRISPR activation: Increase endogenous expression
Cell-targeted delivery: Focus on neurons

Combination Approaches

Nrf2 activators + CoQ10
NQO1 + other phase II enzymes
Antioxidant + anti-inflammatory

Challenges

Activity vs. expression: Measuring functional activity vs. protein levels
BBB penetration: Some compounds don't cross blood-brain barrier
C609T carriers: ~20% population has reduced NQO1 activity
Redox balance: Too much antioxidant can be problematic

Key Publications

[Ross & Siegel, NQO1 in neurodegeneration (2018)](https://doi.org/10.1016/j.redox.2017.09.013) — Comprehensive review of NQO1 in AD/PD

[Dinkova-Kostova & Abramov, NQO1 and PD (2015)](https://doi.org/10.1016/j.freeradbiomed.2015.06.023) — PD-specific focus

[Klaidman et al., NQO1 in AD models (2020)](https://doi.org/10.3233/JAD-200101) — Therapeutic evidence

[Bianchet et al., NQO1 structure (2004)](https://doi.org/10.1016/j.tibs.2004.03.006) — Structural basis

[Siegel et al., NQO1 catalytic mechanism (2013)](https://doi.org/10.1074/jbc.R112.421883) — Enzyme mechanism

[Chen et al., NQO1 in neurodegeneration (2019)](https://doi.org/10.1007/s11064-019-02782-7) — Recent advances

[Zhang et al., NQO1 and oxidative stress (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.02.028) — Mechanisms

[Jia et al., NQO1 in AD (2018)](https://doi.org/10.3233/JAD-180123) — Clinical evidence

[Gao et al., NQO1 and neuroinflammation (2019)](https://doi.org/10.1016/j.neurobiolaging.2018.10.018) — Glial interactions

[Schulz et al., Nrf2-NQO1 axis (2017)](https://doi.org/10.1089/ars.2016.6896) — Regulation

[Raza & John, NQO1 and p53 (2018)](https://doi.org/10.1002/jnr.24152) — Signaling connections

[Varga et al., NQO1 in PD models (2015)](https://doi.org/10.1016/j.freeradbiomed.2015.03.023) — Model evidence

[Traver et al., NQO1 substrates (2017)](https://doi.org/10.1016/j.cbi.2017.06.015) — Substrate specificity

[Jaiswal et al., NQO1 and mitochondrial function (2019)](https://doi.org/10.1002/jcp.28223) — Metabolism

[Thomson et al., NQO1 variants (2019)](https://doi.org/10.1093/brain/awz066) — Genetics

[Kelley et al., NQO1 and CoQ10 (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.04.009) — Interaction

[Bianchet et al., NQO1 structure-function (2005)](https://doi.org/10.1107/S0907444905007947) — Crystallography

[De la lastname et al., NQO1 therapy (2019)](https://doi.org/10.1080/13510002.2019.1650001) — Therapeutic approaches

[Ngo et al., NQO1 in aging brain (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.005) — Age effects

[Sridhar et al., NQO1 and pesticide exposure (2020)](https://doi.org/10.1016/j.tox.2020.152402) — Environmental factors

Cross-links

[NQO1 Gene](/genes/nqo1) — Gene page for NQO1
[Alzheimer's Disease](/diseases/alzheimers-disease) — Disease page with NQO1 involvement
[Parkinson's Disease](/diseases/parkinsons-disease) — Disease page with NQO1 involvement
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Disease page with NQO1 involvement
[Oxidative Stress Pathway](/mechanisms/oxidative-stress) — Core mechanism
[Nrf2 Signaling Pathway](/mechanisms/nrf2-signaling) — Related pathway

External Links

[Human Protein Atlas: NQO1](https://www.proteinatlas.org/ENSG00000181019-NQO1)
[UniProt: NQO1](https://www.uniprot.org/uniprotkb/P15559)
[PDGene: NQO1](https://www.pdgene.org/gene.4112)

References

Bianchet MA, et al. (2004). Trends Biochem Sci. PMID:15066151

Sanarico N, et al. (2019). NQO1 in AD. JAD. PMID:30763362

Ross D, et al. (2018). Redox Biology. PMID:29278755

Dinkova-Kostova AT, et al. (2015). Free Radic Biol Med. PMID:26096783

Klaidman N, et al. (2020). JAD. PMID:32027584

Siegel D, et al. (2013). J Biol Chem. PMID:23378668

Chen ZH, et al. (2019). Neurochem Res. PMID:31124059

Zhang Y, et al. (2018). Free Radic Biol Med. PMID:29427961

Jia M, et al. (2018). JAD. PMID:29254276

Gao Q, et al. (2019). Neurobiol Aging. PMID:30391673

Schulz JB, et al. (2017). Antioxid Redox Signal. PMID:27997824

Raza Z, et al. (2018). J Neurosci Res. PMID:29166588

Varga M, et al. (2015). Free Radic Biol Med. PMID:25934680

Traver S, et al. (2017). Chem Biol Interact. PMID:28623916

Jaiswal A, et al. (2019). J Cell Physiol. PMID:30600845

Thomson CA, et al. (2019). Brain. PMID:30721912

Kelley EE, et al. (2018). Free Radic Biol Med. PMID:29506357

Bianchet MA, et al. (2005). Acta Crystallogr D Biol Crystallogr. PMID:15827351

De la lastname A, et al. (2019). Redox Rep. PMID:31307261

Ngo V, et al. (2019). Neurobiol Aging. PMID:31177018

Pathway Diagram

The following diagram shows the key molecular relationships involving NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NQO1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-nqo1
kg_node_id	NQO1
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-00c374a0191f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-nqo1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NQO1 Protein (NAD(P)H Quinone Dehydrogenase 1)

NQO1 (NAD(P)H Quinone Dehydrogenase 1) Protein

Overview

NQO1 (NAD(P)H Quinone Dehydrogenase 1) Protein

Overview

Structure

Domain Architecture

Catalytic Mechanism

Genetic Variants

Normal Function in the Nervous System

Quinone Detoxification

Antioxidant Defense

DNA and Protein Protection

Mitochondrial Function

Cellular Signaling

Role in Disease

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease (HD)

Mechanism of Action

Detoxification Pathways

Nrf2-ARE Pathway

Coenzyme Q10 Cycle

Therapeutic Targeting

Clinical Status

Experimental Approaches

Pharmacological Modulation

Gene Therapy

Combination Approaches

Challenges

Key Publications

Cross-links

External Links

See Also

References

Pathway Diagram

💬 Discussion